Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism
The objective of this study was to compare the effects of risperidone and olanzapine in schizophrenic patients with intolerant extrapyramidal side effects ( EPS ) on first generation antipsychotics . We conducted an 8-week , rater-blinded , flexible dose study . Seventy patients with schizophrenia , who met the DSM-IV research criteria of having neuroleptic-induced acute dystonia or parkinsonism , were r and omly assigned to  risperidone or olanzapine group . The primary outcome was a comparison of the incidence of concomitant anticholinergic drugs usage between the groups to manage their acute dystonia and parkinsonism . The average doses of risperidone and olanzapine from baseline to study end point were 1.8—3.5 mg/day and 7.7—11.7 mg/day , respectively . There were no significant differences in demographic data , severity of EPS or psychotic symptoms between the groups at baseline assessment . Patients taking risperidone had significantly higher incidence of using anticholinergic drugs to manage acute dystonia or parkinsonism overall during the study ( OR = 5.17 , 95%CI = 1.49—17.88 , P = 0.013 ) . There was no significant between-group difference in the changing of rating scales of EPS and psychotic symptoms . The results of our study favour olanzapine as a better choice in schizophrenic patients with intolerant EPS .  Double-blinded , fixed dose and different ethnical study for EPS-intolerant schizophrenic patients is needed to confirm the results of our study
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .